Jiangsu Hengrui Medicine
600276.SS
#401
Rank
HK$450.33 B
Marketcap
HK$67.85
Share price
0.60%
Change (1 day)
28.26%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2025 (TTM): HK$9.19 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are HK$4.19 Billion. In 2024 the company made an earning of HK$7.73 Billion, an increase over its 2023 earnings that were of HK$5.13 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) HK$9.19 B18.83%
2024 HK$7.73 B50.59%
2023 HK$5.13 B11.35%
2022 HK$4.61 B-13.82%
2021 HK$5.35 B-34.16%
2020 HK$8.13 B16.28%
2019 HK$6.99 B32.92%
2018 HK$5.26 B20.82%
2017 HK$4.35 B23.8%
2016 HK$3.51 B11.25%
2015 HK$3.16 B39.52%
2014 HK$2.26 B20.71%
2013 HK$1.87 B11.46%
2012 HK$1.68 B29.6%
2011 HK$1.29 B31.28%
2010 HK$0.99 B27.89%
2009 HK$0.77 B5.84%
2008 HK$0.73 B79.89%
2007 HK$0.40 B32.93%
2006 HK$0.30 B38.14%
2005 HK$0.22 B21.56%
2004 HK$0.18 B13.95%
2003 HK$0.15 B38.06%
2002 HK$0.11 B